Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe clinical trial record for GRN-1201 with pembrolizumab is displayed, including study details, participation criteria, locations, and outcome measures. The record indicates that the study was terminated because recruitment was too slow.SummaryDifference51%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier was updated from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home link. The previous study record content appears to be removed or hidden.SummaryDifference18%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.